Novartis Said to Near at Least $70-Per-Share Deal for Avidity - Bloomberg.com
- Novartis Said to Near at Least $70-Per-Share Deal for Avidity Bloomberg.com
- Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports CNBC
- Novartis is said to near acquisition of Avidity Biosciences for more than $70 a share (NVS:NYSE) Seeking Alpha
- Novartis set to announce $10bn plus Avidity Biosciences purchase Financial Times
- Novartis Agrees to Buy Avidity Biosciences for $72 Per Share Bloomberg.com